Portfolio Holdings Detail for ISIN IE00B3VWM098

Stock Name / Fund	iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc
Issuer	Blackrock
Entity holding fund	iShares VII Public Limited Company
Entity Type	Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI	549300Q7FFITMZ2PFZ28
ETF Ticker	CUS1(GBX) LSE
ETF Ticker	CUSS(USD) LSE
ETF Ticker	SXRG(EUR) F
ETF Ticker	CSUSS.MI(EUR) CXE
ETF Ticker	CSUSSz(USD) CXE
ETF Ticker	CUSS.LS(USD) CXE
ETF Ticker	CSUSS(EUR) ETF Plus
ETF Ticker	CUS1.L(GBP) LSE
ETF Ticker	CUSS.L(GBP) LSE

Holdings detail for IMVT

Show aggregate IMVT holdings

News associated with IMVT

Immunovant, Inc. (NASDAQ:IMVT) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Immunovant, Inc. (NASDAQ:IMVT – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the twelve ratings firms that are covering the company, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating on the […] - 2025-08-26 04:26:49

Bank of America Lowers Immunovant (NASDAQ:IMVT) Price Target to $30.00

Immunovant (NASDAQ:IMVT – Get Free Report) had its price objective reduced by equities research analysts at Bank of America from $33.00 to $30.00 in a report released on Tuesday,Benzinga reports. The firm currently has a “buy” rating on the stock. Bank of America‘s price objective would suggest a potential upside of 88.80% from the stock’s […] - 2025-08-14 03:07:05

Immunovant Posts 34% R&D Jump in Q1

Key Points- Immunovant’s net loss widened to $0.71 per share (GAAP) in Q1 FY2026 as expenses rose with pipeline expansion. - 2025-08-11 08:27:59

Immunovant, Inc. (NASDAQ:IMVT) Receives $36.40 Average Price Target from Analysts

Immunovant, Inc. (NASDAQ:IMVT – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the eleven ratings firms that are presently covering the stock, Marketbeat.com reports. Three analysts have rated the stock with a hold recommendation, seven have issued a buy recommendation and one has assigned a strong buy recommendation to the […] - 2025-08-04 02:42:53

Analysts Set Immunovant, Inc. (NASDAQ:IMVT) Target Price at $38.33

Immunovant, Inc. (NASDAQ:IMVT – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the ten brokerages that are covering the firm, Marketbeat reports. Two analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. The […] - 2025-07-10 02:50:51

Immunovant, Inc. (NASDAQ:IMVT) Receives Consensus Rating of “Moderate Buy” from Brokerages

Immunovant, Inc. (NASDAQ:IMVT – Get Free Report) has earned an average recommendation of “Moderate Buy” from the ten analysts that are currently covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the […] - 2025-06-12 05:18:48

How The Pieces Add Up: SCHK Headed For $32

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-06-05 07:23:06

ProShare Advisors LLC Buys 3,681 Shares of Immunovant, Inc. (NASDAQ:IMVT)

ProShare Advisors LLC boosted its position in Immunovant, Inc. (NASDAQ:IMVT – Free Report) by 18.8% during the 4th quarter, Holdings Channel.com reports. The firm owned 23,300 shares of the company’s stock after purchasing an additional 3,681 shares during the period. ProShare Advisors LLC’s holdings in Immunovant were worth $577,000 as of its most recent filing […] - 2025-05-26 05:18:59

Immunovant, Inc. (NASDAQ:IMVT) Receives Average Recommendation of “Moderate Buy” from Brokerages

Immunovant, Inc. (NASDAQ:IMVT – Get Free Report) has been given a consensus rating of “Moderate Buy” by the ten ratings firms that are covering the firm, Marketbeat reports. Two analysts have rated the stock with a hold recommendation, seven have given a buy recommendation and one has given a strong buy recommendation to the company. […] - 2025-05-23 05:00:51

Immunovant, Inc. (NASDAQ:IMVT) Shares Purchased by D. E. Shaw & Co. Inc.

D. E. Shaw & Co. Inc. increased its holdings in shares of Immunovant, Inc. (NASDAQ:IMVT – Free Report) by 8.4% in the fourth quarter, Holdings Channel reports. The firm owned 67,669 shares of the company’s stock after buying an additional 5,234 shares during the quarter. D. E. Shaw & Co. Inc.’s holdings in Immunovant were […] - 2025-05-22 04:48:46

The Manufacturers Life Insurance Company Sells 772 Shares of Immunovant, Inc. (NASDAQ:IMVT)

The Manufacturers Life Insurance Company lowered its stake in shares of Immunovant, Inc. (NASDAQ:IMVT – Free Report) by 2.1% during the fourth quarter, HoldingsChannel reports. The firm owned 35,908 shares of the company’s stock after selling 772 shares during the quarter. The Manufacturers Life Insurance Company’s holdings in Immunovant were worth $889,000 as of its […] - 2025-05-15 04:45:06

Invesco Ltd. Lowers Holdings in Immunovant, Inc. (NASDAQ:IMVT)

Invesco Ltd. reduced its position in shares of Immunovant, Inc. (NASDAQ:IMVT – Free Report) by 15.2% in the fourth quarter, Holdings Channel reports. The firm owned 504,032 shares of the company’s stock after selling 90,210 shares during the period. Invesco Ltd.’s holdings in Immunovant were worth $12,485,000 at the end of the most recent reporting […] - 2025-04-22 04:57:06

Geode Capital Management LLC Purchases 4,094 Shares of Immunovant, Inc. (NASDAQ:IMVT)

Geode Capital Management LLC grew its position in Immunovant, Inc. (NASDAQ:IMVT – Free Report) by 0.3% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,515,020 shares of the company’s stock after acquiring an additional 4,094 shares during the quarter. Geode […] - 2025-04-16 04:39:00

Norges Bank Buys Shares of 637,947 Immunovant, Inc. (NASDAQ:IMVT)

Norges Bank purchased a new position in shares of Immunovant, Inc. (NASDAQ:IMVT – Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 637,947 shares of the company’s stock, valued at approximately $15,802,000. A number of other large investors have also […] - 2025-04-08 04:46:59

Peek Under The Hood: DFAC Has 28% Upside

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-04-04 08:47:40

Teacher Retirement System of Texas Acquires 2,373 Shares of Immunovant, Inc. (NASDAQ:IMVT)

Teacher Retirement System of Texas increased its holdings in shares of Immunovant, Inc. (NASDAQ:IMVT – Free Report) by 18.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 15,203 shares of the company’s stock after acquiring an additional 2,373 shares during the quarter. […] - 2025-04-01 04:44:44

Brokerages Set Immunovant, Inc. (NASDAQ:IMVT) Price Target at $41.00

Shares of Immunovant, Inc. (NASDAQ:IMVT – Get Free Report) have been given a consensus recommendation of “Buy” by the ten analysts that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation, eight have issued a buy recommendation and one has given a strong buy recommendation to the […] - 2025-04-01 02:40:43

HC Wainwright Reiterates “Buy” Rating for Immunovant (NASDAQ:IMVT)

Immunovant (NASDAQ:IMVT – Get Free Report)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $51.00 price objective on the stock. HC Wainwright’s target price indicates a potential upside of 159.01% from the company’s previous close. Several other […] - 2025-03-21 04:42:50

Guggenheim Reaffirms Buy Rating for Immunovant (NASDAQ:IMVT)

Guggenheim reiterated their buy rating on shares of Immunovant (NASDAQ:IMVT – Free Report) in a report issued on Monday morning,Benzinga reports. A number of other brokerages have also issued reports on IMVT. Cantor Fitzgerald upgraded shares of Immunovant to a “strong-buy” rating in a research report on Tuesday, March 4th. Jefferies Financial Group assumed coverage […] - 2025-03-11 04:40:47

Immunovant, Inc. (NASDAQ:IMVT) Receives $43.55 Consensus Target Price from Analysts

Shares of Immunovant, Inc. (NASDAQ:IMVT – Get Free Report) have received an average recommendation of “Moderate Buy” from the thirteen ratings firms that are currently covering the company, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy […] - 2025-03-07 04:43:06

Immunovant (NASDAQ:IMVT) Coverage Initiated at Jefferies Financial Group

Equities researchers at Jefferies Financial Group began coverage on shares of Immunovant (NASDAQ:IMVT – Get Free Report) in a research report issued to clients and investors on Monday, MarketBeat.com reports. The brokerage set a “hold” rating and a $20.00 price target on the stock. Jefferies Financial Group’s price objective suggests a potential upside of 8.17% […] - 2025-03-05 05:04:58

Comparing Immunovant (NASDAQ:IMVT) & OKYO Pharma (NASDAQ:OKYO)

Immunovant (NASDAQ:IMVT – Get Free Report) and OKYO Pharma (NASDAQ:OKYO – Get Free Report) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, risk, dividends and institutional ownership. Profitability This table compares Immunovant and OKYO Pharma’s net […] - 2025-03-05 04:20:53

Immunovant, Inc. (NASDAQ:IMVT) Shares Sold by Principal Financial Group Inc.

Principal Financial Group Inc. trimmed its holdings in shares of Immunovant, Inc. (NASDAQ:IMVT – Free Report) by 16.7% in the 4th quarter, HoldingsChannel.com reports. The fund owned 791,863 shares of the company’s stock after selling 159,261 shares during the quarter. Principal Financial Group Inc.’s holdings in Immunovant were worth $19,614,000 as of its most recent […] - 2025-02-25 06:48:54

Guggenheim Cuts Immunovant (NASDAQ:IMVT) Price Target to $44.00

Immunovant (NASDAQ:IMVT – Get Free Report) had its price target dropped by equities researchers at Guggenheim from $46.00 to $44.00 in a research report issued to clients and investors on Monday,Benzinga reports. The firm presently has a “buy” rating on the stock. Guggenheim’s price objective would indicate a potential upside of 127.51% from the company’s […] - 2025-02-12 06:46:57

Immunovant, Inc. (NASDAQ:IMVT) Receives $47.00 Consensus PT from Brokerages

Shares of Immunovant, Inc. (NASDAQ:IMVT – Get Free Report) have been assigned an average recommendation of “Buy” from the twelve ratings firms that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating […] - 2025-02-12 06:09:06

Immunovant (NASDAQ:IMVT) Sets New 1-Year Low on Disappointing Earnings

Immunovant, Inc. (NASDAQ:IMVT – Get Free Report) shares hit a new 52-week low during trading on Monday following a weaker than expected earnings announcement. The stock traded as low as $19.82 and last traded at $19.60, with a volume of 702620 shares trading hands. The stock had previously closed at $20.41. The company reported ($0.76) […] - 2025-02-12 04:14:58

Immunovant, Inc. (NASDAQ:IMVT) Shares Bought by KBC Group NV

KBC Group NV boosted its position in shares of Immunovant, Inc. (NASDAQ:IMVT – Free Report) by 60.1% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,099 shares of the company’s stock after buying an additional 1,163 shares during the quarter. KBC Group NV’s […] - 2025-02-10 16:30:58

iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc IMVT holdings

Date	Number of IMVT Shares Held	Base Market Value of IMVT Shares	Local Market Value of IMVT Shares	Change in IMVT Shares Held	Change in IMVT Base Value	Current Price per IMVT Share Held	Previous Price per IMVT Share Held
2025-09-29 (Monday)	9,820	USD 157,709	USD 157,709
2025-09-26 (Friday)	9,820	USD 159,379	USD 159,379
2025-09-25 (Thursday)	9,820	USD 153,879	USD 153,879	0	USD 2,062	USD 15.67	USD 15.46
2025-09-24 (Wednesday)	9,820	USD 151,817	USD 151,817
2025-09-17 (Wednesday)	9,758	USD 147,443	USD 147,443	0	USD -1,757	USD 15.11	USD 15.29
2025-09-16 (Tuesday)	9,758	USD 149,200	USD 149,200
2025-09-12 (Friday)	9,696	USD 156,687	USD 156,687

Share Trades of IMVT by Blackrock for IE00B3VWM098

Date	Action	Quantity	Market High	Market Low	Likely Trade Price	Likely Trade Value (Profit/Loss)	Average Price previous trades
2025-08-21	SELL	-54			14.840*		19.60 Profit of 1,058 on sale
2025-07-31	BUY	162			16.080*		19.65
2025-06-30	SELL	-108			16.000*		19.96 Profit of 2,156 on sale
2025-06-25	SELL	-54			15.750*		20.04 Profit of 1,082 on sale
2025-06-20	SELL	-108			15.800*		20.14 Profit of 2,175 on sale
2025-05-23	BUY	54			14.460*		20.91
2025-05-19	SELL	-54			14.700*		21.13 Profit of 1,141 on sale
2025-05-15	SELL	-162			13.920*		21.25 Profit of 3,443 on sale
2025-05-12	SELL	-54			14.550*		21.44 Profit of 1,158 on sale
2025-05-09	SELL	-54			14.020*		21.51 Profit of 1,162 on sale
2025-04-30	SELL	-54			16.150*		21.95 Profit of 1,185 on sale
2025-04-24	SELL	-108			15.070*		22.23 Profit of 2,401 on sale
2025-04-17	SELL	-54			15.150*		22.63 Profit of 1,222 on sale
2025-04-15	SELL	-162			15.465*		22.79 Profit of 3,692 on sale
2025-04-14	SELL	-162			15.430*		22.87 Profit of 3,706 on sale
2025-04-09	SELL	-216			14.900*		23.15 Profit of 5,000 on sale
2025-04-07	SELL	-378			14.390*		23.37 Profit of 8,832 on sale
2025-04-04	SELL	-540			14.580*		23.47 Profit of 12,673 on sale
2025-03-31	BUY	54			17.090*		23.73
2025-03-19	SELL	-108			18.880*		24.26 Profit of 2,620 on sale
2025-03-14	SELL	-324			19.520*		24.46 Profit of 7,926 on sale
2025-03-13	SELL	-108			18.790*		24.55 Profit of 2,651 on sale
2025-03-12	SELL	-1,836			19.120*		24.62 Profit of 45,209 on sale
2025-03-07	SELL	-108			20.020*		24.83 Profit of 2,682 on sale
2025-03-06	SELL	-162			19.520*		24.92 Profit of 4,036 on sale
2025-03-03	SELL	-54			18.440*		25.21 Profit of 1,362 on sale
2025-02-28	SELL	-324			20.600*		25.29 Profit of 8,194 on sale
2025-02-26	SELL	-54			20.080*		25.46 Profit of 1,375 on sale
2025-02-25	SELL	-162			19.780*		25.56 Profit of 4,141 on sale
2025-02-18	BUY	270			20.820*		26.01
2025-02-13	BUY	54			19.860*		26.36
2025-02-12	BUY	54			19.220*		26.51
2025-02-11	BUY	162			19.340*		26.66
2025-02-06	BUY	486			20.360*		27.10
2025-01-27	BUY	54			22.400*		28.25
2024-12-30	BUY	270			23.880*		28.78
2024-12-06	BUY	216			28.620*		28.78
2024-12-05	BUY	54			28.400*		28.79
2024-12-04	BUY	270			28.520*		28.80
2024-11-29	BUY	270			28.200*		28.85
2024-11-27	BUY	216			28.730*		28.86
2024-11-26	BUY	54			27.160*		28.94
2024-11-21	BUY	270			26.540*		29.28
2024-11-20	BUY	162			26.170*		29.45
2024-11-18	BUY	648			25.510*		29.96
2024-11-12	BUY	432			29.270*		30.01
2024-11-08	BUY	270			30.650*		29.96
2024-11-07	BUY	810			29.930*		29.96
2024-11-06	BUY	108			31.420*		29.84
2024-10-31	BUY	54			29.260*		29.97

Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of IMVT

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer